Cristcot LLC
🇺🇸United States
Phase 3 Study to Evaluate the Safety and Efficacy of Hydrocortisone Acetate Suppositories
Phase 3
Completed
- Conditions
- Ulcerative Proctitis
- Interventions
- Combination Product: Twice daily placebo suppository administered with Sephure applicatorCombination Product: Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicatorCombination Product: Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Cristcot LLC
- Target Recruit Count
- 618
- Registration Number
- NCT04469686
- Locations
- 🇺🇸
Gastro Health Research, Cincinnati, Ohio, United States
Pharmacokinetics and Bioavailability of Hydrocortisone Acetate Suppositories
- First Posted Date
- 2016-02-02
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- Cristcot LLC
- Target Recruit Count
- 16
- Registration Number
- NCT02671058
© Copyright 2025. All Rights Reserved by MedPath